secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001437749-25-034243
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics' subsidiary Baergic Bio acquired by Axsome for up to $82M milestones plus royalties
--------------------------------------------------------------------------------

- Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.
- Sales-based milestones up to $79M; tiered mid-to-high single digit royalty on global net sales of AXS-17 (formerly BAER-101).
- Avenue expects to receive ~74% of all future payments and royalties.
- Axsome receives worldwide rights to BAER-101 (GABA A PAM) to be evaluated for epilepsy.
- CEO granted 443,578 restricted shares; CFO granted 266,147 restricted shares, fully vesting upon closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000143774925034243/0001437749-25-034243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000143774925034243/atxi20250430_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer